SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Zora Neale Hurston

PatientZora Neale Hurston
Date of birth1959-01-07
IdentifiersMRN HR-ML040-SYN; SSN (made up) 000-40-6213
Document date2026-04-06
AuthorLorraine Abernathy-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review after starting dapagliflozin. [S]

History of Present Illness

Ms. Hurston returns two weeks after starting dapagliflozin and atorvastatin. She is less breathless: she now climbs the stairs at the school without stopping, and her ankles no longer swell by evening. Her home blood pressure average this week is 134/82. She has had no lightheadedness, genital itching or burning on passing urine, and no muscle aches. She weighs herself each morning. Her SNAP benefits were approved, the patient assistance program shipped a 90-day supply of dapagliflozin, and the SHINE counselor helped her apply for Extra Help and the Medicare Savings Program. She can name the BE FAST signs and keeps the card by her telephone. [S]

ElementDetail
Home blood pressureAverage 134/82 mmHg
SymptomsStairs at school without stopping; ankle swelling gone
Medicine effectsNo lightheadedness, genital infection or muscle aches
BenefitsSNAP approved; Extra Help and Medicare Savings Program applications submitted

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations or ankle swelling; breathless only on hurrying
GenitourinaryNegativeNo genital itching or dysuria
MusculoskeletalNegativeNo muscle aches or cramps

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet every morningOne tablet every morningOral route2026-03-09activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morningOne-half tablet every morningOral route2026-03-09activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route2026-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) dailyOne-half tablet dailyOral route2026-04-06activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-06Body height165cmS
2026-04-06Body weight82.6kgS
2026-04-06Body mass index (BMI) [Ratio]30.3kg/m2S
2026-04-06Systolic blood pressure134mm[Hg]S
2026-04-06Diastolic blood pressure82mm[Hg]S
2026-04-06Heart rate76/minS
2026-04-06Respiratory rate16/minS
2026-04-06Body temperature36.7CelS
2026-04-06Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-06Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-04-06Potassium [Moles/volume] in Serum or Plasma3.4mmol/L3.5-5.1 mmol/LLowS
2026-04-06Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.59-1.04 mg/dLNormalS
2026-04-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M63mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-06Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-04-06Magnesium [Mass/volume] in Serum or Plasma1.8mg/dL1.6-2.6 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-04-06; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 134/82, pulse 76; weight 82.6 kg
NeckJugular venous pressure not raised
CardiovascularRegular rhythm; S4
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure.
Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit.
Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of deathactiveconfirmed I11.0S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D.
Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atriumactiveconfirmed I50.32S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit.
Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive)activeconfirmed Z59.41S — Synthetic social need anchored to her documented poverty.
Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented low income in the 1950s.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure in the clinic (seated, average of two readings, large cuff)Every visitCompleted today134/82 mmHg
ExaminationOut-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes)At diagnosis and with each treatment changeCompleted todayHome average 134/82 mmHg
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today82.6 kg; jugular venous pressure not raised; no edema; NYHA I to II
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six monthsCompleted todayTwo weeks after dapagliflozin: sodium 137, potassium 3.4 (low), creatinine 0.98 mg/dL (eGFR 63), magnesium 1.8
Medication safetySGLT2 inhibitor: genital infection, volume depletion and sick-day rulesEvery visitCompleted todayNo genital infection or lightheadedness; sick-day rules reviewed
ImagingECG and echocardiogramAt diagnosis; repeat only with unexplained clinical changeNot indicatedDiagnosis made two weeks ago; no clinical change
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsUp to date54 at diagnosis; next at about three months
LaboratoryLipid panelFour to twelve weeks after starting a statin; then yearlyUp to dateTwo weeks on atorvastatin; panel at the next visit
Self-managementSelf-care: daily weights, less salt, sick-day rules and the BE FAST stroke signsEvery visitCompleted todayWeighs daily; less salt at the table; teaches back the BE FAST signs
Medication safetyMedicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program)Every visitCompleted todayDapagliflozin 90-day supply from patient assistance; Extra Help and Medicare Savings Program applications submitted
Self-managementFood accessEvery visitCompleted todaySNAP approved

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Help with drug costs (Extra Help) (2026); Medicare Savings Programs (2026); SNAP Eligibility (2026)

Follow-up: Metabolic panel in one to two weeks at the clinic laboratory. Review in eight weeks with a metabolic panel, lipid panel and the KCCQ-12. Next scheduled visit 2026-06-01: eight-week review: blood pressure at home and in the clinic, potassium and kidney function, lipids, KCCQ-12 and drug coverage. [S]